Abstract：
Breast cancer is one of the most common neoplasms among women. Anticancer strategies using natural formulations and phytotherapies are promising antitumor treatment alternatives. This review assesses the antitumor effects of curcumin on breast cancer reported in preclinical in vitro and in vivo animal models. We used five databases to search for preclinical studies published up to May 2021. The assessments included the effects of curcumin on the proliferation, viability, and apoptosis of breast cancer cell lineages and on tumor volume. In total, 60 articles met the inclusion criteria. Curcumin administered at different concentrations and via different routes of administration inhibited proliferation, decreased viability, and induced apoptosis in human and animal breast cancer cells. Nanoparticle formulations of curcumin administered orally, via implant, and intraperitoneally reduced the tumor volume of human and murine mammary cells in vivo. Moreover, curcumin nanoformulations exert positive effects on tumor growth inhibition in animal models of breast cancer. Further randomized clinical trials are warranted to assess the efficacy and safety of curcumin formulations for clinical use.
摘要：
乳腺癌是女性最常见的肿瘤之一。使用天然制剂和植物疗法的抗癌策略是有希望的抗肿瘤治疗替代方案。这篇综述评估了姜黄素对临床前体外和体内动物模型报道的乳腺癌的抗肿瘤作用。我们使用了五个数据库来搜索截至2021年5月发表的临床前研究。评估包括姜黄素对增殖的影响，生存能力，和乳腺癌细胞谱系的凋亡和对肿瘤体积的影响。总的来说,60篇文章符合纳入标准。不同浓度和不同给药途径的姜黄素抑制增殖,生存能力下降，并诱导人和动物乳腺癌细胞凋亡。口服姜黄素的纳米颗粒制剂，通过植入物，并腹膜内减少体内人和鼠乳腺细胞的肿瘤体积。此外，姜黄素纳米制剂对乳腺癌动物模型中的肿瘤生长抑制发挥积极作用。需要进一步的随机临床试验来评估姜黄素制剂临床使用的有效性和安全性。
